Abstract:Tumor-reactive CD8 T cells found in cancer patients are frequently dysfunctional, unable to halt tumor growth. Adoptive T cell transfer (ACT), the administration of large numbers of in vitro-generated cytolytic tumor-reactive CD8 T cells, is an important cancer immune therapy being pursued. However, a limitation of ACT is that transferred CD8 T cells often rapidly lose effector function, and despite exciting results in certain malignancies, few ACT clinical trials have shown responses in solid tumors. Here, we developed preclinical cancer mouse models to investigate if and how tumor-specific CD4 T cells can be enlisted to overcome CD8 T cell dysfunction in the setting of ACT. In situ confocal microscopy of color-coded cancer cells, tumor-specific CD8 and CD4 T cells, and antigen presenting cells (APC), combined with functional studies, revealed that the spatial positioning and interactions of CD8 and CD4 T cells, but not their numbers, dictates ACT efficacy and anti-tumor responses. We uncover a new role of antigen-specific CD4 T cells in addition to the known requirement for CD4 T cells during priming/activation of naïve CD8 T cells. CD4 T cells must co-engage with CD8 T cells and APC cross-presenting CD8- and CD4-tumor antigens during the effector phase, forming a three-cell-cluster (triad), to license CD8 T cell cytotoxicity and mediate cancer cell elimination. Triad formation transcriptionally and epigenetically reprogram CD8 T cells, prevent T cell dysfunction/exhaustion, and ultimately lead to the elimination of large established tumors and confer long-term protection from recurrence. When intratumoral triad formation was disrupted, adoptively transferred CD8 T cells could not be reprogrammed, and tumors progressed despite equal numbers of tumor-infiltrating CD8 and CD4 T cells. Strikingly, the formation of CD4 T cell::CD8 T cell::APC triads in tumors of patients with lung cancers treated with immune checkpoint blockade was associated with clinical responses, but not CD4::APC dyads or overall numbers of CD8 or CD4 T cells, demonstrating the importance of triads in non-ACT settings in humans. Our work uncovers intratumoral triads as a key requirement for anti-tumor immunity and a new role for CD4 T cells in CD8 T cell cytotoxicity and cancer cell eradication.

CD4+ T cells in antitumor immunity

The Outstanding Antitumor Capacity of CD4+ T Helper Lymphocytes.

The outstanding antitumor capacity of CD4<SUP>+</SUP> T helper lymphocytes

Roles of CD4+ T cells as mediators of antitumor immunity

CD4+ T cell help in cancer immunology and immunotherapy

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Cytotoxic CD4+ T cells in chronic viral infections and cancer

Identification of human CD4+ T cell populations with distinct antitumor activity

CX3CR1+CD8+ T cells: Key players in antitumor immunity

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4– T Cells

Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment

Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors

Investigating T Cell Immunity in Cancer: Achievements and Prospects

CD8+ T cell-based cancer immunotherapy

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response

Immune resistance orchestrated by the tumor microenvironment

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.